Skip to main content

Supported by an educational grant from Neurocrine Biosciences, Inc.

News

Mara is a 58-year-old woman with a 20-year history of schizoaffective disorder, stab

All News

This infographic, titled "TD Today: Gaps in Recognition & Impact," highlights the disconnect between advances in tardive dyskinesia (TD) care and how often it still goes unrecognized

Tardive dyskinesia (TD) remains a common long-term consequence of prolonged exposure to dopamine receptor-blocking agents, particularl

We want to hear from you!

A new educational quiz from Psych Congress Network highlights the importance of evaluating potential drug-drug interactions

Deutetrabenazine showed significant efficacy and high specificity in inhibiting its primary target, vesicular monoamine transporter type 2 (VMAT2), in functional assessments of the drug’s deuterate

A post hoc analysis found that valbenazine was safe and effective for the long-term treatment of

Key barriers to tardive dyskinesia (TD) diagnosis include a lack of communication with the health care professional, lack of a physical exam, and low educational and socioeconomic status, according

The US Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of